Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK 'value-based' pricing talks start next month

This article was originally published in Scrip

Executive Summary

Negotiations on the UK's new value-based pricing system are set to begin next month, a joint statement from the Association of the British Pharmaceutical Industry and England's Department of Health has confirmed. The industry association and the government will thrash out the landscape for drugs already on the market. They will also discuss whether value-based pricing will encompass oncology drugs that failed to pass muster with NICE, the health technology appraisal body for England and Wales. At present NICE-rejected oncology drugs can get a second chance for funding in England through the Cancer Drugs Fund.

You may also be interested in...



What’s Next After 20 Years Of NICE?

Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.

Profile: Meindert Boysen On What Companies Should Expect From NICE And The Benefits Of Hill Walking

In an exclusive interview with the Pink Sheet, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.

England’s NICE Future Proofs Approach To Using Data

UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.

Topics

UsernamePublicRestriction

Register

SC018360

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel